Louis Cannon, M.D., FACC, FCCP, FACP, FACA, FSCAI

Louis Cannon, MD, is the Founder and Senior Managing Director of BioStar Ventures now early into its fourth fund. BioStars most recent completed fund has successful transactions for more than half of its investments with a double digit IRR; recent acquisitions in the medical device space have included: CVI acquired by Covidien Medtronic; CD Diagnostics acquired by Zimmer; Reverse Medical acquired by Covidien, Embrellae acquired by Edwards, and Ellipse sold to NuVasive; altogether these acquisitions including milestones have yielded an ROI of invested capital of over 4 x to date. Dr Cannon serves on the BOD as well as the audit and compensation committee for Corindus (CVRS: NYSE) and is on the BOD of Olympus Opthalmics, KONA Medical, and New Pace.  Dr Cannon is a former Judith Volkman Scholar in Residence, is the President of the Cardiac and Vascular Research Center of Northern Michigan and is the Senior Program Director for McLaren Northern Michigans’ Heart & Vascular Institute. He has had patents licensed to Medtronic and Boston Scientific and serves on the strategic advisory boards for Fortune 500 companies such as Medtronic, Abbott, Boston Scientific, Johnson and Johnson, as well as other early developing medical technology companies giving him a unique insight into acquirers’ acquisition appetites.